Currently, the standard blood test used to monitor colorectal cancer (CRC) patients for recurrence is carcinoembryonic antigen (CEA). Although CEA has been used for over three decades to monitor patients for cancer relapse and spreading, the test may yield false positive results that can be caused by smoking and other non-cancerous conditions.1
“CEA is insufficiently sensitive to be used alone. It is therefore essential to augment CEA monitoring with another diagnostic modality in order to avoid missed cases…[the goal of monitoring] is not simply the detection of recurrence, but the ability to detect recurrent disease as early as possible to facilitate intervention and cure.”2
Colvera detects the presence of two altered genes, BCAT1 and IKZF1, in ctDNA, that when present show a high concordance of colorectal cancer recurrence. Colvera may help you make more informed decision about whether additional follow-up, such as radiological imaging, should be considered.
In a recent study published in Cancer Medicine, Colvera detected twice the number of recurrent CRC cases compared to CEA. Of 122 patients who were tested after completion of their initial therapy, 28 patients developed a recurrent CRC and Colvera detected recurrence in 19 of these 28 patients compared to only 9 of 28 patients detected by CEA.3
Using Colvera in combination with CEA may provide additional information to help you more confidently monitor your patients and possibly identify CRC recurrence before symptoms present and cancer has spread to other areas of the body.
In a head to head clinical evaluation, Colvera detected
CRC recurrences compared to CEA
- Young P., Womeldorph C, et al. Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: Current status and challenges. Journal of Cancer 2014; 5 (4) 262-271.
- Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, Perera R, Primrose JN, Mant D. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD011134. DOI: 10.1002/14651858.CD011134.pub2.
- Young G., Pedersen S, Mansfield S, et al. A cross sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Medicine 2016; 5(10):2763-2772.